Enhanced antitumor activity of mitomycin C conjugated with anti-alpha-fetoprotein antibody by a novel method of conjugation.
Mitomycin C (MMC) was conjugated to horse anti-rat alpha-fetoprotein (AFP) antibody at the N-1a position through a glutaric acid-derived spacer arm. In vitro studies showed that MMC was spontaneously and slowly released from the conjugate. The conjugate caused a greater inhibition of both the in vitro and in vivo tumor growth of the AFP-producing rat hepatoma AH66 than did a mixture of anti-rat AFP antibody and MMC or a similar conjugate of MMC with normal horse immunoglobulin.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D000906:Antibodies / Q000627:therapeutic use*; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D000922:Immunotoxins; D007700:Kinetics; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy*; D016685:Mitomycin; D008937:Mitomycins / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains; D000509:alpha-Fetoproteins
D000903:Antibiotics, Antineoplastic; D000906:Antibodies; D000922:Immunotoxins; D008937:Mitomycins; D000509:alpha-Fetoproteins; C042774:mitomycin C-anti-alpha-fetoprotein antibody conjugate; D016685:Mitomycin; C042773:1 alpha-(4-(N-succinimidoxycarbonyl)butyryl)mitomycin C